Abstract
The small molecule multi-kinase inhibitor sorafenib has become the standard systemic treatment for patients with advanced hepatocellular carcinoma (HCC) and renal cell carcinoma. Similar to other kinase inhibitors, drug resistance hinders its clinical use; thus, combination therapy to improve sorafenib sensitivity is a promising approach. The present study shows for the first time that the combination of sorafenib and wogonin exerts a significant potentiation of cytotoxicity in a number of human HCC cell lines in a dose-dependent manner. Enhanced cell death was due to potentiation of apoptosis, which was demonstrated by increased apoptotic cell populations, caspase activation and suppression of cell death by the pan-caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl. Sorafenib induced autophagy activation, which was shown by autophagic flux. Suppression of autophagy with the autophagy inhibitors chloroquine or 3-methyladenine significantly enhanced cytotoxicity, suggesting that sorafenib-induced autophagy is cytoprotective. Notably, wogonin effectively inhibited sorafenib-induced autophagy. Altogether, our results indicate that the combination of wogonin and sorafenib effectively kills human HCC cells. This occurs, at least in part, through autophagy inhibition, which potentiates apoptosis. Thus, wogonin could be an ideal candidate for increasing sorafenibs activity in HCC therapy, which warrants further investigation in vivo.
Introduction
Hepatocellular carcinoma (HCC) is a highly aggressive form of liver cancer. For patients with advanced stages, the multi-kinase inhibitor sorafenib is the standard systemic treatment. However, its clinical effectiveness is often short-lived because cancer cells frequently develop resistance to the drug. One way cancer cells survive sorafenib treatment is through autophagy—a cellular "self-eating" process that normally recycles damaged components but can be hijacked by tumors to survive stress. This study investigates whether wogonin, a natural compound derived from the medicinal herb Scutellaria baicalensis, can sensitize HCC cells to sorafenib by inhibiting this protective autophagy.
Methodology
The researchers tested their hypothesis across four established human HCC cell lines: Hep3B, Bel-7402, HepG2, and SMMC-7721.
- Cytotoxicity Assays: Lactate Dehydrogenase (LDH) release assays quantified cell death.
- Synergy Analysis: The Combination Index (CI) was calculated to determine if the two drugs were synergistic (CI < 1).
- Flow Cytometry: Annexin V-FITC and Propidium Iodide (PI) staining distinguished between healthy and apoptotic cells.
- Western Blotting: Used to track PARP cleavage (apoptosis marker) and LC3-II/p62 (autophagy markers).
- Chemical Inhibitors: Z-VAD (pan-caspase inhibitor) confirmed the role of apoptosis, while Chloroquine (CQ) or 3-methyladenine (3-MA) validated the role of autophagy.
Results
Synergistic Cytotoxicity
The combination of wogonin and sorafenib demonstrated significant mathematical synergy across all tested cell lines. In SMMC-7721 cells, the CI reached as low as 0.003, indicating extreme synergy. As shown in the figures below, adding wogonin to sorafenib treatment dramatically increased cell death compared to either drug alone.
In Bel-7402 cells, sorafenib alone caused less than 20% cell death, but the addition of 40 µM wogonin increased cell death to approximately 80%. Similar results were observed in HepG2 cells, where the combination treatment significantly outperformed monotherapy.
Mechanism of Action: Autophagy Inhibition
The study confirmed that sorafenib alone induces autophagy in HCC cells as a cytoprotective "shield." Blocking this autophagy with known inhibitors (CQ or 3-MA) increased cell death, proving its protective role. Crucially, wogonin was found to act as a potent autophagy inhibitor, suppressing the sorafenib-induced increase of LC3-II. By removing this survival mechanism, wogonin allows sorafenib to more effectively trigger apoptosis, evidenced by a massive increase in PARP cleavage and caspase activation.
Discussion and Future Outlook
While these in vitro results are promising, the study was conducted entirely on cell cultures. The complex environment of a living organism could alter these effects. Furthermore, while wogonin clearly inhibits autophagy, the exact molecular target it binds to remains unidentified. Future research must move into in vivo animal models to determine safe dosing levels and confirm if this synergy translates to clinical efficacy in human trials.
Summary updated